| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IPO8 |
| Uniprot No | O15397 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1037aa |
| 氨基酸序列 | MDLNRIIQALKGTIDPKLRIAAENELNQSYKIINFAPSLLRIIVSDHVEFPVRQAAAIYLKNMVTQYWPDREPPPGEAIFPFNIHENDRQQIRDNIVEGIIRSPDLVRVQLTMCLRAIIKHDFPGHWPGVVDKIDYYLQSQSSASWLGSLLCLYQLVKTYEYKKAEEREPLIIAMQIFLPRIQQQIVQLLPDSSYYSVLLQKQILKIFYALVQYALPLQLVNNQTMTTWMEIFRTIIDRTVPPETLHIDEDDRPELVWWKCKKWALHIVARLFERYGSPGNVTKEYFEFSEFFLKTYAVGIQQVLLKILDQYRQKEYVAPRVLQQAFNYLNQGVVHSITWKQMKPHIQNISEDVIFSVMCYKDEDEELWQEDPYEYIRMKFDIFEDYASPTTAAQTLLYTAAKKRKEVLPKMMAFCYQILTDPNFDPRKKDGALHVIGSLAEILLKKSLFKDQMELFLQNHVFPLLLSNLGYLRARSCWVLHAFSSLKFHNELNLRNAVELAKKSLIEDKEMPVKVEAALALQSLISNQIQAKEYMKPHVRPIMQELLHIVRETENDDVTNVIQKMICEYSQEVASIAVDMTQHLAEIFGKVLQSDEYEEVEDKTVMAMGILHTIDTILTVVEDHKEITQQLENICLRIIDLVLQKHVIEFYEEILSLAYSLTCHSISPQMWQLLGILYEVFQQDCFEYFTDMMPLLHNYVTIDTDTLLSNAKHLEILFTMCRKVLCGDAGEDAECHAAKLLEVIILQCKGRGIDQCIPLFVQLVLERLTRGVKTSELRTMCLQVAIAALYYNPDLLLHTLERIQLPHNPGPITVQFINQWMNDTDCFLGHHDRKMCIIGLSILLELQNRPPAVDAVVGQIVPSILFLFLGLKQVCATRQLVNREDRSKAEKADMEENEEISSDEEETNVTAQAMQSNNGRGEDEEEEDDDWDEEVLEETALEGFSTPLDLDNSVDEYQFFTQALITVQSRDAAWYQLLMAPLSEDQRTALQEVYTLAEHRRTVAEAKKKIEQQGGFTFENKGVLSAFNFGTVPSNN |
| 预测分子量 | 119,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IPO8重组蛋白的参考文献示例(注：以下内容为示例性虚构，实际文献需通过学术数据库检索确认)：
1. **文献名称**: "Functional Characterization of Recombinant IPO8 in mRNA Nuclear Export"
**作者**: Zhang L, et al.
**摘要**: 研究通过大肠杆菌表达系统成功制备了重组IPO8蛋白，并验证其作为核转运蛋白在mRNA出核过程中的关键作用，证实其与特定RNA结合蛋白的相互作用。
2. **文献名称**: "Structural Insights into IPO8-Mediated Transport Mechanisms"
**作者**: Smith J, et al.
**摘要**: 利用冷冻电镜解析重组IPO8蛋白的三维结构，揭示其与核转运受体结合的结构域，为理解其底物选择性提供分子基础。
3. **文献名称**: "IPO8 Recombinant Protein Promotes Cancer Metastasis via TGF-β Signaling"
**作者**: Wang H, et al.
**摘要**: 体外实验表明，重组IPO8蛋白通过增强TGF-β信号通路的核转位，促进肿瘤细胞侵袭，提示其在癌症治疗中的潜在靶点价值。
4. **文献名称**: "Viral RNA Hijacking of IPO8 for Nuclear Export in Influenza Infection"
**作者**: Lee K, et al.
**摘要**: 研究发现流感病毒NS1蛋白与重组IPO8结合，劫持其核输出功能以促进病毒RNA转运，为抗病毒治疗提供新思路。
**提示**：以上为模拟示例，实际文献请通过PubMed、Google Scholar等平台以关键词“IPO8 recombinant protein”或“IPO8 nuclear transport”检索。
IPO8 (Importin 8) is a member of the importin β family of nuclear transport receptors, which play critical roles in shuttling macromolecules between the nucleus and cytoplasm. It is encoded by the IPO8 gene and functions as a nuclear transporter for specific cargoes, including proteins and RNA molecules. Unlike classical importins, IPO8 exhibits unique substrate specificity, mediating the nuclear import of certain transcription factors (e.g., STAT1) and RNA-binding proteins involved in gene regulation. Studies suggest it may also participate in RNA transport, particularly for subsets of microRNAs and small RNAs, linking it to post-transcriptional regulatory processes.
Recombinant IPO8 protein is engineered for in vitro studies to dissect its molecular interactions, structural features, and transport mechanisms. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), it retains functional domains essential for binding RanGTP, cargo recognition, and nucleoporin interactions. This tool has been pivotal in mapping IPO8’s role in TGF-β signaling, immune responses, and viral infection pathways, where nuclear transport of viral components depends on host importins. Additionally, recombinant IPO8 aids in structural studies, revealing how its HEAT repeats facilitate conformational changes during cargo loading.
Emerging research implicates IPO8 in diseases, including cancer, where its overexpression correlates with tumor progression and drug resistance. Recombinant IPO8 enables high-throughput screening for inhibitors targeting nuclear transport dysregulation. Its versatility also extends to diagnostics, as autoantibodies against IPO8 are detected in autoimmune disorders. Despite progress, questions remain about its cargo diversity and tissue-specific functions, driving ongoing demand for recombinant IPO8 as a research reagent.
×
